Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25132906 | 0.93 | HDAC6 (0.36) | HDAC6HDAC1HDAC2MAOAMAOB | |
| SCHEMBL256557 | 0.85 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL16378479 | 0.84 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL1926793 | 0.84 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL19544584 | 0.82 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL14291315 | 0.81 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL6445026 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL14224824 | 0.81 | CA14 (0.40) | HDAC6HDAC1HDAC2MAOAMAOB | |
| SCHEMBL336495 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL1689401 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CTSDCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LTD (GB) | 2026-02-26 | — | — | US | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| EP-4532485-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| US-20240391934-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LTD (GB) | 2024-11-28 | — | — | US | disclosed |
| US-20240383916-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, AND PYRIMIDINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LTD (GB) | 2024-11-21 | — | — | US | disclosed |
| US-12103937-B2 | Substituted pyridines and pyridazines as TYK2 inhibitors | SUDO BIOSCIENCES LIMITED (GB) | 2024-10-01 | — | — | US | disclosed |
| US-12084458-B2 | Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors | SUDO BIOSCIENCES LIMITED (GB) | 2024-09-10 | — | — | US | disclosed |
| EP-4347032-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117813302-A | Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1379514-A2 | 5-MEMBERED HETEROCYCLES, PREPARATION AND APPLICATION THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-01-14 | — | — | EP | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002083656-A2 | 5-MEMBERED HETEROCYCLES, PREPARATION AND USE THEREOF AS MAO INHIBITORS AND LIPID PEROXIDATION INHIBITORS, PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-10-24 | — | — | WO | disclosed |
| EP-1228760-A2 | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-07 | — | — | EP | disclosed |
| EP-1223933-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001026656-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND USE THEREOF AS MONOAMINE OXIDASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-04-19 | — | — | WO | disclosed |
| US-5861429-A | MITICIDES AND ANTHELMINTICS | SANKYO COMPANY, LIMITED (JP) | 1999-01-19 | — | — | US | disclosed |
| EP-0300189-B1 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0300189-A2 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | HDAC6 1185/4885HDAC1 370/4885HDAC2 1498/4885 |
| US-12103937-B2 | Substituted pyridines and pyridazines as TYK2 inhibitors | TYK2, PDXK, TPX2 | HDAC6 1240/4885HDAC1 1003/4885HDAC2 360/4885 |
| US-20240383916-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, AND PYRIMIDINES AS TYK2 INHIBITORS | TYK2, PDXK, TPX2 | HDAC6 1885/4885HDAC1 1598/4885HDAC2 419/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | HDAC6 2045/4885HDAC1 4624/4885HDAC2 4678/4885 |
| US-20240391934-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES AS TYK2 INHIBITORS | TYK2, PDXK, TPX2 | HDAC6 1240/4885HDAC1 1003/4885HDAC2 360/4885 |
| US-12084458-B2 | Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors | TYK2, PDXK, TPX2 | HDAC6 1885/4885HDAC1 1598/4885HDAC2 419/4885 |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, CSNK2A3, CSNK2B | HDAC6 769/4885HDAC1 815/4885HDAC2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.